title: [Effects of transcatheter arterial chemoembolization with pingyangmycin-lipiodol emulsion on VX2 liver tumors in rabbits].
abstract: To evaluate the changes induced in tumor tissue, the feeding artery, and neovascularization upon  pingyangmycin-lipiodol emulsion treatment via transcatheter arterial chemoembolization (TACE) using the rabbit VX2 liver cancer model. The VX2 liver tumor model was established in 28 rabbits, and baseline tumor volume (V1, in mm3) was measured by spiral scan computed tomography (CT). Then, the rabbits were randomly divided into four groups (n = 7 each) and administered intraarterial therapies of: ultrafluid lipoidol embolization (group A); pingyangmycin (group B); pingyangmycin-lipiodol emulsion (group C); or saline (group D). All rabbits were sacrificed seven days later, and the response to therapy was determined by measuring the tumor volume (V2, in mm3), calculating the tumor growth rate, detecting expression of the vascular endothelial growth factor (VEGF) tumor biomarker, and performing histological analysis of the microvessel density (MVD) in the liver. Prior to therapy, the average V1 of the groups was statistically similar (A: 389.8+/-167.3, B: 404.1+/-184.9, C: 355.1+/-158.3, D: 378.1+/-189.0; (F = 0.257, P more than 0.05). In contrast, after therapy the average V2 of the groups was significantly different (A: 922.6+/-32.9, B: 665.9+/-99.9, C: 349.5+/-177.8, D: 1403.5+/-411.2; F = 26.23, P less than 0.05), as was the tumor growth ratio (A: 1.4, B: 0.6, C: -0.02, D: 2.7) and the mean positive ratio of VEGF (A: 57.1%, B: 42.9%, C: 28.6%, D: 100%; F = 8.407, P less than 0.05). MVD was highest in group D and lowest in group C (all, P less than 0.05). Bivariate correlation analysis revealed a positive correlation between VEGF expression and MVD (r = 0.743, P less than 0.01). Pingyangmycin exerts anti-tumor effects in the rabbit VX2 liver cancer model, but is more effective when administered as the combination therapy of pingyangmycin-lipiodol emulsion with TACE.
authors.affiliation: Department of Intervention Center, Chongqing Medical University, Chongqing, China.
authors.forename: Xi
authors.initials: X
authors.lastname: Liu
authors.forename: Xiao-ping
authors.initials: XP
authors.lastname: Luo
authors.forename: Wen-ting
authors.initials: WT
authors.lastname: Cao
authors.forename: Hao
authors.initials: H
authors.lastname: Deng
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016461:Chemoembolization, Therapeutic / Q000379:methods*; D004655:Emulsions; D004998:Ethiodized Oil / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D007459:Iodized Oil / Q000008:administration & dosage / Q000627:therapeutic use; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D055806:Microvessels; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D011817:Rabbits; D011897:Random Allocation; D047368:Tumor Burden / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; D004655:Emulsions; D042461:Vascular Endothelial Growth Factor A; D001761:Bleomycin; C025703:bleomycetin; D007459:Iodized Oil; D004998:Ethiodized Oil